Prescribing information

 

In this section, you will find a collection of resources designed to support the use of LUCENTIS in day-to-day practice.

These resources include materials for HCPs as well as materials for your patients, to help them better understand their diagnosis, as well as their treatment. Please scroll down to find the patient resources and a link that can be shared to provide your patients with access to these materials.

Resources for HCPs

 

Thumbnail of Diabetic Macular Oedema (DMO) booklet.

Diabetic Macular Oedema (DMO) booklet

A booklet specifically designed to provide information about DMO to nurses. 

Download

Thumbnail of Understanding DMO slide deck.

Understanding DMO

A slide deck that provides information on diabetic macular oedema (DMO) and information on LUCENTIS.

Download

Thumbnail of Understanding RVO slide deck.

Understanding RVO

A slide deck that provides information on retinal vein occlusion (RVO) and information on LUCENTIS.

Download

 

Icon of a webinar.

Explore our series of on-demand webinars that cover LUCENTIS and provide information on ophthalmology, with a particular focus on DMO. Topics include:

  • Restarting clinics
  • Auditing and managing DMO
  • Wolverhampton audit data
  • Royal Derby audit data
  • Lucentis in DMO 

Watch webinars

Icon of a microphone with audio coming out.

Explore our podcast episodes that cover LUCENTIS and provide information on the impact of COVID-19 on retina service. Topics include:

  • Communicating with patients in times of crisis
  • Virtual clinics
  • From audit to service implementation
  • The impact of COVID-19 on DMO patients

Listen to podcasts

 

Resources for patients

Please share the link below to provide your patients with access to the patient resources found below. Please note that the patient resources are only to be shared with patients who have been prescribed LUCENTIS.

Share Link

 

Lucentis parent/guardian booklet (ROP) thumbnail

LUCENTIS parent/guardian booklet (ROP)*

A leaflet on retinopathy of prematurity (ROP) which can be shared with parents of infants who receive treatment with LUCENTIS.*

Download

Thumbnail image of understanding DMO booklet

Understanding diabetic macular oedema (DMO) & what to expect from your LUCENTIS treatment

A leaflet that can be shared with patients who have been prescribed LUCENTIS as a treatment for visual impairment due to DMO. The leaflet includes information about the disease, LUCENTIS treatment and answers frequently asked questions.

Download

Thumbnail image of Lucentis patient information DMO/PDR booklet

LUCENTIS patient information booklet (DMO/PDR)

A booklet containing important safety information for patients who have been prescribed LUCENTIS for the treatment of visual impairment due to diabetic macular oedema (DMO).

View

 

Thumbnail image of Lucentis (wAMD) patient information booklet

LUCENTIS patient information booklet (wAMD)

A booklet containing important safety information for patients who have been prescribed LUCENTIS for the treatment of wet (neovascular) age-related macular degeneration (wAMD).

View

Thumbnail image of Lucentis (RVO) patient information booklet

LUCENTIS patient information booklet (RVO)

A booklet containing important safety information for patients who have been prescribed LUCENTIS for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO).

View

Thumbnail image of Lucentis patient information (CNV) booklet

LUCENTIS patient information booklet (CNV)

A booklet containing important safety information for patients who have been prescribed LUCENTIS for the treatment of visual impairment due to choroidal neovascularisation (CNV).

View

 

Indications1

LUCENTIS 0.5 mg is indicated in adults for:

  • The treatment of neovascular (wet) age-related macular degeneration (AMD)
  • The treatment of visual impairment due to diabetic macular oedema (DMO)
  • The treatment of proliferative diabetic retinopathy (PDR)
  • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
  • The treatment of visual impairment due to choroidal neovascularisation (CNV).

 

*LUCENTIS 0.2 mg is indicated in preterm infants for:

  • The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

 

CNV, choroidal neovascularisation; DMO, diabetic macular oedema; HCP, healthcare professional; PDR, proliferative diabetic retinopathy; ROP, retinopathy of prematurity; RVO, retinal vein occlusion; VEGF, vascular endothelial growth factor; wAMD, wet age-related macular degeneration.

Reference

  1. LUCENTIS® (ranibizumab) Summary of Product Characteristics, July 2020.
Rate this content: 
No votes yet
UK | August 2021 | 144393
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]